Low Production Capacity of Interleukin-10 Associates With the Metabolic Syndrome and Type 2 Diabetes
The Leiden 85-Plus Study
- Eric van Exel1,
- Jacobijn Gussekloo1,
- Anton J.M. de Craen12,
- Marijke Frölich3,
- Annetje Bootsma-van der Wiel1 and
- Rudi G.J. Westendorp1
- 1Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, The Netherlands
- 2Department of Clinical Epidemiology, Leiden University Medical Center, The Netherlands
- 3Department of Clinical Chemistry, Leiden University Medical Center, The Netherlands
Abstract
It has been suggested that the metabolic syndrome and type 2 diabetes are manifestations of the inflammatory host response. This host response is orchestrated by the production of pro- and anti-inflammatory cytokines that are under genetic control. We therefore hypothesized that a low production capacity of interleukin-10 (IL-10), a centrally operating cytokine with strong anti-inflammatory properties, associates with the metabolic syndrome and type 2 diabetes in old age. In the current study, 599 inhabitants of the city of Leiden, age 85 years, were visited at their place of residence. The production capacity of the anti-inflammatory cytokine IL-10 was assessed in a whole-blood assay in which lipopolysaccharide was used as a stimulus. Serum concentrations of lipids, lipoproteins, glucose, and HbA1c were determined, and a history of type 2 diabetes was obtained. Serum concentrations of total cholesterol, LDL cholesterol, triglycerides, glucose, and HbA1c gradually decreased over strata representing higher IL-10 production capacity, whereas the concentration of HDL cholesterol gradually increased (all P < 0.01). The odds ratio for type 2 diabetes was 2.7 (95% confidence interval 1.5–4.9) when subjects with the lowest IL-10 production capacity were compared with those with the highest IL-10 production capacity. These findings showed that low IL-10 production capacity (i.e., a pro-inflammatory response) is associated with the metabolic syndrome and type 2 diabetes.
Footnotes
-
Address correspondence and reprint requests to J. Gussekloo, M.D., Ph.D., Leiden University Medical Center, Section of Gerontology and Geriatrics, C2-R, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: jgussekloo{at}lumc.nl or leiden85plus{at}lumc.nl..
Received for publication 1 November 2001 and accepted in revised form 4 January 2002.
CI, confidence intervals; IL, interleukin; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α.
- DIABETES











